News

Peginesatide, a synthetic, PEGylated peptidic compound, is a erythropoiesis stimulating agent (ESA) that binds and activates the erythropoietin receptor. The NDA submission is based on data from two

Additionally, NIH has selected Viamet’s novel antifungal compounds for inclusion in the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program. Viamet president and

Cogane is an orally bioavailable neurotrophic factor inducer that crosses the blood-brain barrier and shows neuroprotective effects. The interim results of Cogane show promising activity in preclinical in

Febuxostat, a non-purine selective inhibitor of xanthine oxidase is used to treat chronic hyperuricemia in gout patients. Teijin Pharma signed a licensing agreement with SK Chemicals in July

SEBVI Technology uses Epstein Barr Virus for immortalizing and isolating circulating human B cells from the blood of immunocompetent individuals which secrete antigen-specific IgG antibodies. PX’T plans to

The Phase 3 trial which aims at over all survival, is a double-blind, randomized trial involved around 430 patients to compare the safety and efficacy of perifosine +

Currently, mipomersen is in late-stage development for the reduction of LDL cholesterol (LDL-C). Genzyme and Isis Pharma said that if approved the drug will be marketed under Kynamro

The joint venture which will focus on developing, manufacturing and promoting generic drugs, will be 51% owned by Fujifilm and 49% by the Indian drug maker. The new

Chasse-sur-Rhone provides for process scale-ups, the supply of clinical batches and the regular production of low volume compounds under cGMP. Freeport site performs custom manufacturing services from late